^
Association details:
| Biomarker: | AR-V7 positive |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | cabazitaxel (Microtubule inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
615P - Circulating tumor cells (CTC) gene expression and plasma androgen receptor (AR) copy number (CN) in cabazitaxel-treated metastatic castration-resistant prostate cancer (mCRPC)
Published date:
09/13/2021
Excerpt:
Baseline CTC biomarkers may be considered useful prognosticators for cabazitaxel-treated mCRPC pts. Our results suggest that cabazitaxel 25 mg/sqm should be preferred in AR-V7-pos mCRPC.
Trial ID:
Source:
Title:
Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Excerpt:
...we prospectively enrolled patients with metastatic CRPC initiating taxane chemotherapy (docetaxel or cabazitaxel)...In AR-V7-positive men, taxanes appear to be more efficacious than enzalutamide or abiraterone therapy,...In AR-V7-positive patients, PSA responses were higher in taxane-treated vs enzalutamide- or abiraterone-treated men (41% vs 0%; P < .001), and PSA PFS and PFS were significantly longer in taxane-treated men (HR, 0.19 [95% CI, 0.07-0.52] for PSA PFS, P = .001; HR, 0.21 [95% CI, 0.07-0.59] for PFS, P = .003).
DOI:
10.1001/jamaoncol.2015.1341
